Cis-Diamminedichloroplatinum Ii
Transitional Cell Carcinoma
Explore 3 assets in Transitional Cell Carcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Astellas Pharma Global Development, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03288545CT.gov A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | — | Terminated | — | — | — |
NCT02300610CT.gov Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Transitional Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Astellas Pharma Global Development, Inc. | P1/2 | B · 57 |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Astellas Pharma Global Development, Inc. | P2 | BB |
| Muamycin | UroGen Pharma Ltd. | P3 | B |
| Carboplatin | Astellas Pharma Global Development, Inc. | P1/2 | B |
| Brivanib | Bristol-Myers Squibb | P2 | B |
| Pembrolizumab | Carisma Therapeutics Inc | P1/2 | B |
| Vinflunine | Bristol-Myers Squibb | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
+11 more in the Transitional Cell Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Astellas Pharma Global Development, Inc.BB
- MuamycinUroGen Pharma Ltd.B
- CarboplatinAstellas Pharma Global Development, Inc.B
- BrivanibBristol-Myers SquibbB
- PembrolizumabCarisma Therapeutics IncB
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Transitional Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-transitional-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →